TIME magazine has revealed its prestigious TIME100 Health 2026 list, recognizing the 100 most influential people in global health. In the 'Titans' category, Daniel O'Day, President and CEO of the biopharmaceutical company Gilead Sciences, stands out for his pivotal role in transforming the global paradigm of HIV prevention. The TIME recognition is based on an unprecedented scientific breakthrough: the arrival of the first option for semi-annual HIV prevention (twice a year). This long-acting injectable method represents a break from the past of daily oral therapies. Under O'Day's leadership, the company not only secured FDA approval for this lenacapavir-based technology but also deployed a strategy to ensure this innovation reaches countries with the highest burden of the disease. The recognition of Daniel O'Day reinforces the urgency for local health systems to accelerate regulatory frameworks to adopt these innovations in our region, where access to long-acting prevention methods can change the course of new infections.
Daniel O'Day of Gilead Sciences Named to TIME100 Health 2026 List
TIME magazine recognized Daniel O'Day, head of Gilead Sciences, for developing a semi-annual injectable HIV prevention drug that could be a game-changer for low- and middle-income countries.
